PDCD1 and thoracic cancer: Over the past decade, monoclonal antibodies targeting programmed cell death protein 1 (PD-1) or its ligand PD-L1 have been globally approved for clinical use, either as monotherapy or in combination with chemotherapy, for the treatment of various malignancies, including thoracic cancers such as mesothelioma (Table 1).